Kurt Gustafson Net Worth

The estimated Net Worth of Kurt A Gustafson is at least $4.26 Million dollars as of 6 March 2024. Mr. Gustafson owns over 15,000 units of Spectrum Pharmaceuticals stock worth over $20,607 and over the last 15 years he sold SPPI stock worth over $1,116,773. In addition, he makes $3,122,820 as Chief Financial Officer and Executive Vice President at Spectrum Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gustafson SPPI stock SEC Form 4 insiders trading

Kurt has made over 21 trades of the Spectrum Pharmaceuticals stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 15,000 units of SPPI stock worth $160,950 on 6 March 2024.

The largest trade he's ever made was selling 36,971 units of Spectrum Pharmaceuticals stock on 15 March 2022 worth over $26,249. On average, Kurt trades about 4,173 units every 69 days since 2010. As of 6 March 2024 he still owns at least 20,007 units of Spectrum Pharmaceuticals stock.

You can see the complete history of Mr. Gustafson stock trades at the bottom of the page.

Kurt Gustafson biography

Kurt A. Gustafson serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Gustafson has served as our Executive Vice President and Chief Financial Officer since June 2013. He brings to Spectrum more than 25 years of diverse experience in corporate finance, including 15 years in senior management roles leading the finance departments of biopharmaceutical industry organizations. Prior to joining Spectrum, Mr. Gustafson served as Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc., a publicly-traded biopharmaceutical company. Before joining Halozyme in 2009, Mr. Gustafson worked at Amgen for over 18 years, holding various positions in finance including Treasurer, VP Finance and Chief Financial Officer of Amgen International based in Switzerland. Mr. Gustafson is currently a member of the Board of Directors of Xencor, Inc., a clinical-stage biopharmaceutical company and is also a member of the Board of Directors of ChromaDex, Inc., a proprietary ingredient company.

What is the salary of Kurt Gustafson?

As the Chief Financial Officer and Executive Vice President of Spectrum Pharmaceuticals, the total compensation of Kurt Gustafson at Spectrum Pharmaceuticals is $3,122,820. There are 2 executives at Spectrum Pharmaceuticals getting paid more, with Joseph Turgeon having the highest compensation of $5,697,230.

How old is Kurt Gustafson?

Kurt Gustafson is 52, he's been the Chief Financial Officer and Executive Vice President of Spectrum Pharmaceuticals since 2013. There are 9 older and 5 younger executives at Spectrum Pharmaceuticals. The oldest executive at Spectrum Pharmaceuticals, Inc. is Dolatrai Vyas, 76, who is the Independent Director.

What's Kurt Gustafson's mailing address?

Kurt's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.

Insiders trading at Spectrum Pharmaceuticals

Over the last 21 years, insiders at Spectrum Pharmaceuticals have traded over $34,101,027 worth of Spectrum Pharmaceuticals stock and bought 60,000 units worth $132,000 . The most active insiders traders include Rajesh C Md Shrotriya, Raymond W Cohen, and Thomas J Riga. On average, Spectrum Pharmaceuticals executives and independent directors trade stock every 26 days with the average trade being worth of $68,584. The most recent stock trade was executed by Nora Brennan on 26 May 2023, trading 32,387 units of SPPI stock currently worth $35,626.

What does Spectrum Pharmaceuticals do?

spectrum's core mission is to bring pharmaceutical products to patients for unmet medical needs. to this mission, we bring our years of drug development expertise, coupled with the insight of working in many different oncology indications. spectrum and its subsidiaries have six marketed oncology/hematology products, three for different types of non-hodgkins lymphoma, one for advanced metastatic colorectal cancer, one for a certain type of acute lymphoblastic leukemia (all) and one for multiple myeloma. there are two products in late-stage development, as well as a broad and diversified portfolio of proprietary drugs in various stages of development, all with a focus on oncology and hematology.

Complete history of Mr. Gustafson stock trades at Chromadex Corp, Halozyme Therapeutics, Spectrum Pharmaceuticals, and Xencor Inc

Spectrum Pharmaceuticals executives and stock owners

Spectrum Pharmaceuticals executives and other stock owners filed with the SEC include:

• Joseph Turgeon,
  President, Chief Executive Officer, Director
• Thomas Riga,
  Chief Operating Officer, Chief Commercial Officer, Executive Vice President
• Kurt Gustafson,
  Chief Financial Officer, Executive Vice President
• Keith McGahan,
  Senior Vice President, Chief Legal Officer, Corporate Secretary
• Francois Lebel,
  Executive Vice President, Chief Medical Officer
• Thomas J. Riga,
  Pres, CEO & Director
• Kurt A. Gustafson,
  Exec. VP & CFO
• Dr. Francois J. Lebel FRCPC, M.D.,
  Exec. VP & Chief Medical Officer
• Keith M. McGahan J.D., L.L.M.,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• William Ashton,
  Independent Chairman of the Board
• Bernice Welles,
  Independent Director
• Jeffrey Vacirca,
  Independent Director
• Dolatrai Vyas,
  Independent Director
• Elizabeth Czerepak,
  Independent Director
• Seth Fischer,
  Independent Director
• Lyndah Dreiling,
  Senior Vice President, Clinical Development
• Dr. Lyndah K. Dreiling M.B.A., M.D.,
  Sr. VP of Clinical Devel.
• Lisa A. Croissant,
  VP of Sales
• Alberto Dejesus,
  VP of Marketing
• Bimal R. Shah,
  VP of Corp. & Bus. Devel.
• Anthony E Iii Maida,
  Director
• Raymond W Cohen,
  Director
• Stuart Mitchell Krassner,
  Director
• Gilles Gagnon,
  Director
• Luigi Md Lenaz,
  President, Oncology Division
• Juhyun Lim,
  Director
• Jeff L Vacirca,
  Director
• Ann C Phd Kessler,
  Director
• Armin M Kessler,
  Director
• Lee F Md Ph D Allen,
  Chief Medical Officer
• Joseph Kenneth Keller,
  EVP & Chief Operating Officer
• Carol Phd Ocleireacain,
  Director
• Paul H Phd Silverman,
  Director
• Shyam K Kumaria,
  Vice President Finance
• Mark J Glasky,
  Director
• Krishan K Arora,
  Director
• Eric L Phd Nelson,
  Director
• John L Mcmanus,
  VP,Finance, Strategic Planning
• Rajesh C Md Shrotriya,
  Ch, Pres. and Chief Exec. Off.
• Julius A Vida,
  Director
• Dilip J Md Phd Mehta,
  Director
• Richard Fulmer,
  Director
• James Shields,
  Chief Commercial Officer
• Brett L Scott,
  Acting Chief Financial Officer
• Anton Gueth,
  Director
• Mitchell P. Cybulski,
  Director
• George F Tidmarsh,
  CSO AND HEAD OF R&D OPERATIONS
• Nora Brennan,
  See Remarks